AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 187.73B |
| Revenue (ttm) | 50.87B |
| Net Income (ttm) | 7.19B |
| Shares Out | n/a |
| EPS (ttm) | 4.60 |
| PE Ratio | 26.11 |
| Forward PE | 15.81 |
| Dividend | 2.93 (2.42%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 13,093 |
| Average Volume | 13,361 |
| Open | 123.45 |
| Previous Close | 123.10 |
| Day's Range | 121.15 - 123.55 |
| 52-Week Range | 111.00 - 158.20 |
| Beta | 0.17 |
| RSI | 47.75 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India’s Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import an...
Boost for AstraZeneca after successful trial of experimental blood pressure drug
Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of hypertension.
AstraZeneca's baxdrostat meets key goals in late-stage trial for hypertension
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension. The trial included patient...
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically mean...
AstraZeneca drug lowers high BP in late-stage study; shares rise
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmake...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor
The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.
Trump's Tariff Talk Keeps Markets on Edge
The FTSE 100 opened 22 points up this morning, despite threats of pharma and metals tariffs with stark implications for major stocks on the blue chip index. President Trump has said that an announceme...
Artelo Biosciences Analyst See It As An Emerging Biotech
D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ: ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20 . Analyst Jason Kolbert wrote, “We continue ...
What's Behind The Recent Rally In IonQ Stock?
IonQ Inc. (NYSE: IONQ) shares climbed above $47.85 Tuesday morning before pulling back. The stock is still up approximately 13.5% over the past month. Here’s a look at what’s driving the recent price...
AstraZeneca: Just What The Doctor Ordered
Top global stories this week: Banco Santander, Alibaba, AstraZeneca among notable names
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Why AstraZeneca Stock Got Thumped on Thursday
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2218899804-b82cc3c6fc7f442fb508daa6c804cff9.jpg)
Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks
Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
In a high-stakes maneuver that could reshape the oncology landscape, AstraZeneca Plc (NASDAQ: AZN) is reportedly in talks with Summit Therapeutics Inc. (NASDAQ: SMMT) about a partnership worth up to...
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.
New London IPOs hit 28-year low amid AstraZeneca exit concerns
More than $100 billion worth of London-listed companies have announced or executed plans to move to New York in recent years.
Wise Becomes the Latest UK Giant to Eye a Transatlantic Escape
Wise plans to move its primary listing from London to the US for better capital access, joining AstraZeneca and others in doing so. The post Wise Becomes the Latest UK Giant to Eye a Transatlantic Esc...
Price Over Earnings Overview: AstraZeneca
In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $71.17, after a 0.41% decrease. Over the past month, the stock fell by 2.51% , and in the past year, by 7.98% . With performance l...
If AstraZeneca goes to the US it will be a major blow for London and Labour
Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy Three years ago Pascal Soriot received the ultimate accolade for turning around AstraZe...